Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:35:07 2024-04-26 am EDT			5-day change	1st Jan Change
27.21 ^EUR	+0.11%		+1.15%	-3.06%

Apr. 26	FRESENIUS SE : Jefferies reiterates its Buy rating	ZD
Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Fresenius : Participations in affiliated and associated companies 2023

March 14, 2024 at 08:34 am EDT

Participations in affiliated and associated companies

Fresenius SE & Co. KGaA

Bad Homburg v. d. H.

As at December 31st 2023

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1

Bad Homburg v. d. H.

61352

Content		Page
1.	Affiliated domestic companies
	1.1	Fresenius Corporate	1
	1.2	Fresenius Kabi	4
	1.3	Fresenius VAMED	6
	1.4	Fresenius HELIOS	20
2.	Affiliated consolidated foreign companies
	2.1	Fresenius Corporate	62
	2.2	Fresenius Kabi	64
	2.3	Fresenius VAMED	80
	2.4	Fresenius HELIOS	90
3.	Affiliated non consolidated foreign companies
	3.1	Fresenius Kabi	108
	3.2	Fresenius VAMED	110
4.	Associated companies & other investments
	4.1	Fresenius Corporate	117
	4.2	Fresenius Kabi	118
	4.3	Fresenius VAMED	120
	4.4	Fresenius HELIOS	128

Agenda
a	=	No annual financial statement available
b	=	Value as of March 31 of the reporting period
c	=	Value as of June 30 of the reporting period
d	=	Value as of September 30 of the reporting period
e	=	No data of equity or net profit/loss, but IFRS closing on level of HELIOS Kliniken GmbH
f	=	No actual data of the reporting available
g	=	These companies make use of exemption rule § 264 b HGB
h	=	These companies make use of exemption rule § 264 (3) HGB
i	=	Value as of December 31 of the preceding reporting period
j	=	Consolidated value for subgroup Fresenius Kabi Pharmaceuticals Holding, Inc.
k	=	No data of equity or net profit/loss, but closing on level of FK Pharmaceuticals Holding, Inc.
l	=	Consolidated value for subgroup Fresenius Kabi Argentina S.A.
m	=	No data of equity or net profit/loss, but closing on level of Fresenius Kabi Argentina S.A.
n	=	Consolidated value for subgroup Fresenius Kabi Italia S.p.A.
o	=	No data of equity or net profit/loss, but closing on level of Fresenius Kabi Italia S.p.A.
p	=	Consolidated value for subgroup FHC (Holdings) Ltd.
q	=	No data of equity or net profit/loss, but closing on level of FHC (Holdings) Ltd.
r	=	These companies are consolidated due to contractual arrangements.
s	=	No data of equity or net profit/loss, but IFRS closing on level of HELIOS Healthcare Spain S.L.U.
t	=	This company is consolidated due to the majority of the voting rights
u	=	Value as of July 31 of the reporting period
v	=	No data of equity or net profit/loss, but IFRS closing on level of HELIOS Fertility Spain S.L.U.

Fresenius SE & Co. KGaA

List of affiliated and associated companies as of 31.12.2023

Domestic affiliated companies of business segment Fresenius Corporate

			Direct and	Equity	Net profit/loss
			indirect	31.12.2023	2023 converted at
No.	Company		interest	converted at	spot rate at
			%	spot rate at	bal. sheet date
				bal. sheet date	KEUR
				KEUR

Consolidated financial statements - with profit & loss transfer agreement
1	Fresenius Digital Technology GmbH	(h)	100	7,221	0
	Bad Homburg v. d. H.
	Germany
	(indirect interest through no.		10)
2	Fresenius ProServe GmbH	(h)	100	5,115,487	0
	Bad Homburg v. d. H.
	Germany
Consolidated financial statements - without profit & loss transfer agreement
3	Fresenius Immobilien Verwaltung Objekt Schweinfurt GmbH		100	10,759	3,819
	Bad Homburg v. d. H.
	Germany
4	Fresenius Immobilien Verwaltung Objekt St. Wendel GmbH		100	18,615	7,366
	Bad Homburg v. d. H.
	Germany
5	Fresenius Immobilien-Verwaltungs-GmbH		100	78	3
	Bad Homburg v. d. H.
	Germany

Fresenius SE & Co. KGaA

List of affiliated and associated companies as of 31.12.2023

Domestic affiliated companies of business segment Fresenius Corporate

			Direct and	Equity	Net profit/loss
			indirect	31.12.2023	2023 converted at
No.	Company		interest	converted at	spot rate at
			%	spot rate at	bal. sheet date
				bal. sheet date	KEUR
				KEUR

6	Fresenius Immobilien-Verwaltungs-GmbH & Co. Objekt Friedberg 2	(g)	100	1,772	0
	KG
	Bad Homburg v. d. H.
	Germany
7	Fresenius Immobilien-Verwaltungs-GmbH & Co. Objekt Friedberg	(g)	100	5,817	0
	KG
	Bad Homburg v. d. H.
	Germany
8	Fresenius Medical Care Management AG		100	6,674	-3,291
	Bad Homburg v.d.H.
	Germany
9	ProServe Krankenhaus Beteiligungsgesellschaft mbH & Co. KG	(g)	100	12,272	0
	Baierbrunn
	Germany
	(indirect interest through no.		2)
Not consolidated financial statements - with profit & loss transfer agreement
10	Fresenius Versicherungsvermittlungs GmbH		100	7,585	0
	Bad Homburg v. d. H.
	Germany
11	Hyginus Publisher GmbH		100	26	0
	Bad Homburg v. d. H.
	Germany

Fresenius SE & Co. KGaA

List of affiliated and associated companies as of 31.12.2023

Domestic affiliated companies of business segment Fresenius Corporate

		Direct and	Equity	Net profit/loss
		indirect	31.12.2023	2023 converted at
No.	Company	interest	converted at	spot rate at
		%	spot rate at	bal. sheet date
			bal. sheet date	KEUR
			KEUR

Not consolidated financial statements - without profit & loss transfer agreement
	12 Fresenius Hochschulstiftung für Gesundheitsmanagement	100	25	0
	gemeinnützige GmbH
	Bad Homburg v. d. H.
	Germany

Fresenius SE & Co. KGaA

List of affiliated and associated companies as of 31.12.2023

Domestic affiliated companies of business segment Fresenius Kabi

			Direct and	Equity	Net profit/loss
			indirect	31.12.2023	2023 converted at
No.	Company		interest	converted at	spot rate at
			%	spot rate at	bal. sheet date
				bal. sheet date	KEUR
				KEUR

Consolidated financial statements - with profit & loss transfer agreement
	13 Fresenius HemoCare GmbH		100	14,019	0
	Bad Homburg v. d. H.
	Germany
	(indirect interest through no.		14)
	14 Fresenius Kabi AG	(h)	100	3,014,447	0
	Bad Homburg
	Germany
	15 Fresenius Kabi Deutschland GmbH	(h)	100	962,879	0
	Bad Homburg v. d. H.
	Germany
	(indirect interest through no.		14)
	16 Fresenius Kabi Logistik GmbH	(h)	100	20,803	0
	Friedberg
	Germany
	(indirect interest through no.		14)
	17 Fresenius Kabi MedTech Services GmbH		100	4,491	0
	Alzenau
	Germany
	(indirect interest through no.		14)

Fresenius SE & Co. KGaA

List of affiliated and associated companies as of 31.12.2023

Domestic affiliated companies of business segment Fresenius Kabi

		Direct and	Equity	Net profit/loss
		indirect	31.12.2023	2023 converted at
No.	Company	interest	converted at	spot rate at
		%	spot rate at	bal. sheet date
			bal. sheet date	KEUR
			KEUR

	18 medi1one medical gmbh	100	2,692	0
	Fellbach
	Germany
	(indirect interest through no.	15)

Fresenius SE & Co. KGaA

List of affiliated and associated companies as of 31.12.2023

Domestic affiliated companies of business segment Fresenius Vamed

		Direct and	Equity	Net profit/loss
		indirect	31.12.2023	2023 converted at
No.	Company	interest	converted at	spot rate at
		%	spot rate at	bal. sheet date
			bal. sheet date	KEUR
			KEUR

Consolidated financial statements - with profit & loss transfer agreement
	19 ostsee resort damp GmbH	100	64,135	0
	Damp
	Germany
	(indirect interest through no.	65)
	20 VAMED Care Deutschland GmbH	100	597	0
	Damp
	Germany
	(indirect interest through no.	68)
	21 VAMED Fachpflege Schleswig GmbH	95	4,189	0
	Schleswig
	Germany
	(indirect interest through no.	68)
	22 VAMED Kids in Pflege Geesthacht GmbH	100	25	0
	Geesthacht
	Germany
	(indirect interest through no.	24)
	23 VAMED Klinik Bad Berleburg GmbH	95	10,960	0
	Bad Berleburg
	Germany
	(indirect interest through no.	65)

Fresenius SE & Co. KGaA

List of affiliated and associated companies as of 31.12.2023

Domestic affiliated companies of business segment Fresenius Vamed

		Direct and	Equity	Net profit/loss
		indirect	31.12.2023	2023 converted at
No.	Company	interest	converted at	spot rate at
		%	spot rate at	bal. sheet date
			bal. sheet date	KEUR
			KEUR

	24 VAMED Klinik Geesthacht GmbH	95	13,149	0
	Geesthacht
	Germany
	(indirect interest through no.	65)
	25 VAMED Klinik Hagen-Ambrock GmbH	100	7,021	0
	Hagen
	Germany
	(indirect interest through no.	65)
	26 VAMED Klinik Hattingen GmbH	100	5,378	0
	Hattingen
	Germany
	(indirect interest through no.	65)
	27 VAMED Klinik Hohenstücken GmbH	100	6,697	0
	Brandenburg an der Havel
	Germany
	(indirect interest through no.	65)
	28 VAMED Klinik Kipfenberg GmbH	100	6,989	0
	Kipfenberg
	Germany
	(indirect interest through no.	65)
	29 VAMED Klinik Schloss Pulsnitz GmbH	95	6,201	0
	Pulsnitz
	Germany
	(indirect interest through no.	65)

Attachments

Original Link
Original Document
Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 14 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 March 2024 12:33:09 UTC.

Latest news about Fresenius SE & Co. KGaA

FRESENIUS SE : Jefferies reiterates its Buy rating	Apr. 26	ZD
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
FRESENIUS SE : Warburg Research reiterates its Buy rating	Apr. 24	ZD
FRESENIUS SE : Goldman Sachs sticks Neutral	Apr. 23	ZD
Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA.	Apr. 22	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
FRESENIUS SE : Receives a Buy rating from Jefferies	Apr. 22	ZD
Barclays reads 'Overweight' for Fresenius SE - Target 35 Euro	Apr. 22	DP
FRESENIUS SE : Barclays reiterates its Buy rating	Apr. 22	ZD
FRESENIUS SE : Berenberg keeps its Buy rating	Apr. 22	ZD
Positive trend of FMC and Fresenius continues	Apr. 22	DP
FRESENIUS SE : Gets a Neutral rating from JP Morgan	Apr. 18	ZD
Lauterbach wants to press ahead with hospital reform despite differences	Apr. 17	DP
State report warns of risks in hospital reform	Apr. 17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	Apr. 17	ZD
Warnings against cutbacks in hospital reform	Apr. 17	DP
Federal and state governments to discuss hospital reform again	Apr. 17	DP
FRESENIUS SE : Gets a Buy rating from Deutsche Bank	Apr. 16	ZD
STOXX 600 nears six-week low on geopolitical jitters; Ericsson shines	Apr. 16	RE
Fresenius at a two-month high - Tyenne launch and fantasy figures	Apr. 16	DP
Fresenius at two-month high - Tyenne launch a milestone	Apr. 16	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Cannabis law and clinic atlas in the Bundesrat	Mar. 22	DP
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT

Chart Fresenius SE & Co. KGaA

Duration

Period

More charts

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-07 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.21 EUR

Average target price

36.22 EUR

Spread / Average Target

+33.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B
EUROFINS SCIENTIFIC SE	-3.97%	11.66B

Other Healthcare Facilities & Services